skip to main content

Spacer device technique — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardRespiratory TherapeuticsSpacer device techniqueGPhC CRA

A patient with previous anaphylaxis to cow’s-milk protein, but no lactose intolerance, is prescribed Flixotide Accuhaler. Which excipient assessment is correct?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: EThe lactose contains milk protein, so the prescription requires an alternative

Lactose intolerance concerns carbohydrate digestion and does not exclude an IgE-mediated reaction to contaminating milk protein. The Flixotide Accuhaler SmPC states that its lactose contains milk protein. Following previous milk-protein anaphylaxis, the prescription should be clarified and a suitable alternative formulation or device selected.

Reference: Flixotide Accuhaler Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/846/smpc; NHS SPS: Understanding excipients in medicines: https://sps.nhs.uk/articles/understanding-excipients-in-medicines/